Sign in →

Test Code QFT4 QuantiFERON-TB Gold Plus, Blood


Advisory Information


This test is not recommended for use for diagnosis of active tuberculosis (TB) infection. It can be used as an aid to detect latent TB infection.



Specimen Required


Supplies:

-Standard Altitude: QuantiFERON-TB Gold Plus Collection Kit (T794)

-High Altitude: QuantiFERON-TB Gold Plus High Altitude Collection Kit (T795)

Collection Instructions:

1. Special collection, incubation, and centrifugation procedures must be followed.

2. For blood collection options (1-tube collection or 4-tube collection) and specimen transport instructions, see Mycobacterium tuberculosis Infection Determination by QTB Gold Plus Collection and Processing Instructions (T688); available in Special Instructions.


Secondary ID

113563

Useful For

Indirect test for Mycobacterium tuberculosis infection, to be used in conjunction with risk assessment, radiography, and other medical and diagnostic evaluations

Method Name

Enzyme-Linked Immunosorbent Assay (ELISA)

Reporting Name

QuantiFERON-Tb Gold Plus, B

Specimen Type

Whole blood

Specimen Minimum Volume

4 mL-1 mL per tube (4 tubes)

Specimen Stability Information

Specimen Type Temperature Time
Whole blood Refrigerated 28 days

Reject Due To

Hemolysis

NA

Lipemia

NA

Icterus

NA

Other

Specimen submitted not following kit guidelines

Clinical Information

Latent tuberculosis infection (LTBI) is a noncommunicable, asymptomatic condition that persists for many years in individuals and may progress to active tuberculosis disease, particularly in immunosuppressed patients. The primary goal for diagnosis of LTBI is to initiate medical treatment in order to prevent progression to active disease. Historically, detection of LTBI has been done using the tuberculin skin test (TST). The TST has certain limitations however, including subjective interpretation, limited sensitivity in immunosuppressed patients, and the possibility of false-positive results in individuals who have received the bacille Calmett-Guerin (BCG) vaccine or are infected with other mycobacteria.

 

The QuantiFERON-TB Gold Plus (QFT-Plus) test is an interferon (IFN)-gamma release assay (IGRA), which assesses the cell-mediated immune response to 2 Mycobacterium tuberculosis complex antigens, ESAT-6 and CFP-10, by measuring IFN-gamma levels in plasma. These 2 proteins are absent from all BCG strains and from most nontuberculosis mycobacteria with the exception of M kansasii, M szulgai and M marinum. Individuals infected with M tuberculosis complex agents, including M tuberculosis, M bovis, M africanum, M microti, M caprae, and M canetti, usually have lymphocytes in their blood that recognize these specific antigens and this recognition leads to the generation and secretion of IFN-gamma. This cytokine is subsequently detected and quantified using an IFN-gamma enzyme-linked immunosorbent assay.

 

In an M tuberculosis infection, CD4+ T-cells play a critical role in immunological control through secretion of IFN-gamma. The prior version of the QFT-Plus assay, the QuantiFERON-TB Gold In-Tube (QFT-Gold) assay, only detected IFN-gamma secreted from CD4+ T-cells. Evidence now supports a role for CD8+ T-cells in host defense against M tuberculosis infection by likewise producing IFN-gamma, but by also stimulating macrophages to suppress the growth of M tuberculosis, to kill infected cells and to directly lyse intracellular M tuberculosis bacteria. IFN-gamma-producing M tuberculosis specific CD8+ T cells have been detected in subjects with LTBI and in patients with active TB. ESAT-6 and CFP-10 specific CD8+ T-cells have also been more frequently described in patients with active tuberculosis (TB) versus patients with LTBI, and have been detected in HIV-positive patients and children with TB disease.

 

The QFT-Plus assay has 2 distinct TB antigen tubes: TB Antigen Tube 1 (TB1) and TB Antigen Tube 2 (TB2). Both tubes contain peptide antigens from ESAT-6 and CFP-10 for stimulation of a CD4+ T-cell IFN-gamma response. However, the TB2 tube also contains an additional set of ESAT-6 and CFP-10 peptides specifically designed to stimulate a CD8+ T-cell response.

 

For the most up-to-date information regarding use of IGRAs, refer to the most recent guidelines on the Diagnosis of Tuberculosis in Adults and Children from the American Thoracic Society, the Infectious Diseases Society of America, the Centers for Disease Control and Prevention by DM Lewinsohn and colleagues.(1)

Reference Values

Negative

Interpretation

A single positive result by this test should not be used solely to diagnose latent tuberculosis (TB). Results should be used in conjunction with risk assessment, radiography, and other medical and diagnostic evaluations.

 

Positive:

Interferon-gamma (IFN-gamma) response to Mycobacterium tuberculosis antigens detected, suggesting infection with M tuberculosis. Positive results in patients at low-risk for TB should be interpreted with caution and repeat testing on a new sample should be considered as recommended by the 2017 ATS/IDSA/CDC Clinical Practice Guidelines for Diagnosis of Tuberculosis in Adults and Children.(1) False-positive results may occur in patients with prior infection with M marinum, M szulgai, or M kansasii.

 

Negative:

No IFN-gamma response to M tuberculosis antigens was detected. Infection with M tuberculosis is unlikely. A single negative result does not exclude infection with M tuberculosis. In patients at high risk for M tuberculosis infection, a second test should be considered in accordance with the 2017 ATS/IDSA/CDC Clinical Practice Guidelines for Diagnosis of Tuberculosis in Adults and Children.(1)

 

Indeterminate due to Low Mitogen Value:

Indeterminate due to a low IFN-gamma level in the mitogen (positive control) tube. This may occur due to a low lymphocyte count, reduced lymphocyte activity, or inability of the patient's lymphocytes to generate IFN-gamma.

 

Indeterminate due to High Nil value:

Indeterminate due to a high level of IFN-gamma in the Nil (negative control) tube. This may occur due to heterophile antibody effects or nonspecific, circulating IFN-gamma in the patient's blood sample. Repeat testing on a new specimen is suggested.

Clinical Reference

1. Lewinsohn DM, Leonard MK, LoBue PA, et al: Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. Clin Infect Dis 2017 Jan 15;64(2):e1-e33

2. Moon HA, Gaur RL, Tien SS, et al: Evaluation of QuantiFERON-TB Gold Plus in Health Care Workers in a Low-Incidence Setting. J Clin Micobiol 2017;55(6):1650-1657

3. Telisinghe L, Amofa-Sekyi M, Maluzi K, et al: The sensitivity of the QuantiFERON-TB Gold Plus assay in Zambian adults with active tuberculosis. Int J Tuberc Lung Dis 2017;21(6):690-696

Day(s) and Time(s) Performed

Monday through Friday; 9 a.m.

Analytic Time

2 days

Performing Laboratory

Mayo Medical Laboratories in Rochester

Test Classification

This test has been cleared or approved by the U.S. Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.

CPT Code Information

86480

LOINC Code Information

Test ID Test Order Name Order LOINC Value
QFT4 QuantiFERON-Tb Gold Plus, B 71775-1

 

Result ID Test Result Name Result LOINC Value
QFTQ2 QuantiFERON-Tb Gold Plus Result 71773-6
DEXQE TB1 Ag minus Nil Result 64084-7
DEXQF TB2 Ag minus Nil Result 88517-8
DEXQG Mitogen minus Nil Result 71774-4
DEXQH Nil Result 71776-9

Forms

If not ordering electronically, complete, print, and send a General Request Form (T239) with the specimen (http://www.mayomedicallaboratories.com/it-mmfiles/general-request-form.pdf).